In an open-label extension (FOREST-HCM) of 172 people with obstructive hypertrophic cardiomyopathy taking aficamten for ≥48 weeks, mean KCCQ Overall Summary Score rose by 18.8 points at week 48. Angina and EQ-5D scores also improved from week 12. There was no control group.
RCTn = 172
Weiner et al. Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM